Other formats:
BibTeX
LaTeX
RIS
@article{1852759,
author = {Ahuja, Sukriti and Saxena, Sandeep and Akduman, Levent and Meyer, Carsten H and Kružliak, Peter and Khanna, Vinay K},
article_location = {LONDON},
article_number = {1},
doi = {http://dx.doi.org/10.1186/s40942-019-0179-6},
keywords = {Area under curve; Biomarker; Diabetic retinopathy; Receiver operator characteristic curve; Severity; Vascular endothelial growth factor},
language = {eng},
issn = {2056-9920},
journal = {INTERNATIONAL JOURNAL OF RETINA AND VITREOUS},
title = {Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy},
url = {https://journalretinavitreous.biomedcentral.com/articles/10.1186/s40942-019-0179-6},
volume = {5},
year = {2019}
}
TY - JOUR
ID - 1852759
AU - Ahuja, Sukriti - Saxena, Sandeep - Akduman, Levent - Meyer, Carsten H - Kružliak, Peter - Khanna, Vinay K
PY - 2019
TI - Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy
JF - INTERNATIONAL JOURNAL OF RETINA AND VITREOUS
VL - 5
IS - 1
SP - 1-6
EP - 1-6
PB - BMC
SN - 20569920
KW - Area under curve
KW - Biomarker
KW - Diabetic retinopathy
KW - Receiver operator characteristic curve
KW - Severity
KW - Vascular endothelial growth factor
UR - https://journalretinavitreous.biomedcentral.com/articles/10.1186/s40942-019-0179-6
N2 - BackgroundElevated serum vascular endothelial growth factor (VEGF) levels are associated with diabetic retinopathy (DR). Serum VEGF levels correlate with vitreous levels. Neuroretinal changes occur even before the appearance of vascular signs in DR. Role of VEGF as a biomarker for DR has not been assessed. Serum VEGF as a biomarker for severity of DR, was evaluated for the first time.MethodsConsecutive cases of type 2 diabetes mellitus [without DR, (no DR, n=38); non-proliferative DR, (NPDR, n=38); proliferative DR, (PDR, n=40)] and healthy controls (n=40) were included. Serum VEGF was measured using enzyme linked immunosorbent assay. Accuracy of VEGF as a biomarker for severity of retinopathy was measured using the area under the receiver operator characteristic (ROC) curve.ResultsSerum VEGF levels in controls, No DR, NPDR and PDR groups showed significant incremental trend from 138.96 +/- 63.37 pg/ml (controls) to 457.18 +/- 165.69 pg/ml (PDR) (F=48.47; p<0.001). Serum VEGF levels were observed to be significantly elevated even before DR had set in clinically. ROC for serum VEGF levels was significant in discriminating between the cases and the controls and had good accuracy in discerning between subjects with and without retinopathy. The area under curve (AUC +/- SE) for discrimination was significant: (a) cases and controls (n=156): AUC=0.858 +/- 0.029, p<0.001; (b) DR (NPDR+PDR) and No DR (n=116): AUC=0.791 +/- 0.044, p<0.001; and (c) NPDR and PDR (n=78): AUC=0.761 +/- 0.056, p<0.001, with over 90% projected sensitivity and specificity at various cut off values.Conclusion Serum VEGF level is a simple, effective laboratory investigative test in predicting the onset of DR in eyes showing no evidence of DR and serves as a reliable biomolecular biomarker for severity of DR.
ER -
AHUJA, Sukriti, Sandeep SAXENA, Levent AKDUMAN, Carsten H MEYER, Peter KRUŽLIAK and Vinay K KHANNA. Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy. \textit{INTERNATIONAL JOURNAL OF RETINA AND VITREOUS}. LONDON: BMC, 2019, vol.~5, No~1, p.~1-6. ISSN~2056-9920. Available from: https://dx.doi.org/10.1186/s40942-019-0179-6.
|
